Gotham Asset Management LLC Has $31.49 Million Stock Position in Bristol Myers Squibb Company $BMY

Gotham Asset Management LLC lifted its position in Bristol Myers Squibb Company (NYSE:BMY) by 14.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 698,224 shares of the biopharmaceutical company’s stock after acquiring an additional 90,238 shares during the period. Gotham Asset Management LLC’s holdings in Bristol Myers Squibb were worth $31,490,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the company. Darwin Wealth Management LLC purchased a new stake in Bristol Myers Squibb in the 2nd quarter worth about $25,000. Harbor Capital Advisors Inc. grew its stake in Bristol Myers Squibb by 107.2% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 313 shares in the last quarter. Total Investment Management Inc. acquired a new position in shares of Bristol Myers Squibb in the 2nd quarter valued at about $38,000. Twin Peaks Wealth Advisors LLC purchased a new stake in shares of Bristol Myers Squibb in the second quarter worth approximately $40,000. Finally, Bank of Jackson Hole Trust boosted its holdings in shares of Bristol Myers Squibb by 352.2% during the third quarter. Bank of Jackson Hole Trust now owns 1,040 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 810 shares during the period. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Up 1.1%

Shares of Bristol Myers Squibb stock opened at $59.73 on Tuesday. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $62.89. The company has a quick ratio of 1.14, a current ratio of 1.26 and a debt-to-equity ratio of 2.32. The stock has a 50 day moving average price of $58.37 and a two-hundred day moving average price of $51.55. The stock has a market capitalization of $121.63 billion, a P/E ratio of 17.31, a PEG ratio of 0.17 and a beta of 0.26.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). The firm had revenue of $12.50 billion during the quarter, compared to the consensus estimate of $12.24 billion. Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The company’s revenue for the quarter was up 1.3% compared to the same quarter last year. During the same period in the prior year, the business earned $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. The ex-dividend date is Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio is 73.04%.

Analysts Set New Price Targets

Several research analysts have weighed in on BMY shares. UBS Group reiterated a “buy” rating and issued a $70.00 price objective on shares of Bristol Myers Squibb in a research note on Friday, March 6th. Citigroup boosted their price target on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “neutral” rating in a report on Friday, February 6th. Truist Financial set a $65.00 price objective on Bristol Myers Squibb in a report on Wednesday, December 3rd. Scotiabank restated a “sector perform” rating and issued a $60.00 target price (up from $53.00) on shares of Bristol Myers Squibb in a research note on Friday, January 9th. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $57.00 target price (up from $51.00) on shares of Bristol Myers Squibb in a research report on Tuesday, December 2nd. Nine analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $61.00.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.